FEMY
Femasys Inc.
Medical - Instruments & Supplies
Market Cap$13M
5Y Perf.-94.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FEMY vs BLFS
Revenue, margins, valuation, and 5-year total return — side by side.
BLFS
BioLife Solutions, Inc.
Medical - Instruments & Supplies
Market Cap$1.13B
5Y Perf.-48.1%
FEMY vs BLFS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FEMY | BLFS |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $13M | $1.13B |
| Revenue (TTM) | $2M | $100M |
| Net Income (TTM) | $-19M | $-10M |
| Gross Margin | 62.0% | 64.0% |
| Operating Margin | -7.7% | -10.9% |
| Forward P/E | — | 156.4x |
| Total Debt | $5M | $18M |
| Cash & Equiv. | $9M | $33M |
FEMY vs BLFS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FEMY
BLFS
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Femasys Inc. (FEMY) | 100 | 5.5 | -94.5% |
| BioLife Solutions, … (BLFS) | 100 | 51.9 | -48.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FEMY vs BLFS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BLFS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Femasys Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
FEMY
Femasys Inc.
The Income Pick
FEMY is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.10
- Rev growth 40.8%, EPS growth 44.0%, 3Y rev CAGR 23.9%
- Lower volatility, beta 1.10, Low D/E 80.0%, current ratio 4.53x
Best for: income & stability and growth exposure
BLFS
BioLife Solutions, Inc.
The Long-Run Compounder
BLFS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 12.2% 10Y total return vs FEMY's -96.3%
- -10.5% margin vs FEMY's -8.1%
- +8.3% vs FEMY's -60.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FEMY | 40.8% revenue growth vs BLFS's 17.0% |
| Quality / Margins | BLFS | -10.5% margin vs FEMY's -8.1% |
| Stability / Safety | FEMY | Beta 1.10 vs BLFS's 1.67 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BLFS | +8.3% vs FEMY's -60.6% |
| Efficiency (ROA) | BLFS | -2.6% ROA vs FEMY's -116.3%, ROIC -2.8% vs -347.4% |
FEMY vs BLFS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FEMY vs BLFS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBLFSLAGGINGFEMY
FEMYFemasys Inc.
0leads
BLFSBioLife Solutions, In…
4leads
6 Total Categories
CATEGORYLEADERvs FEMYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BLFS4/5
Valuation MetricsMultiples, price ratios, and targets
BLFS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BLFS7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BLFS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BLFS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
BLFS is the larger business by revenue, generating $100M annually — 43.5x FEMY's $2M. Profitability is closely matched — net margins range from -10.5% (BLFS) to -8.1% (FEMY). On growth, FEMY holds the edge at +39.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $100M |
| EBITDAEarnings before interest/tax | -$17M | -$7M |
| Net IncomeAfter-tax profit | -$19M | -$10M |
| Free Cash FlowCash after capex | -$19M | $11M |
| Gross MarginGross profit ÷ Revenue | +62.0% | +64.0% |
| Operating MarginEBIT ÷ Revenue | -7.7% | -10.9% |
| Net MarginNet income ÷ Revenue | -8.1% | -10.5% |
| FCF MarginFCF ÷ Revenue | -8.4% | +10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +39.9% | +14.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.9% | — |
BLFS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
BLFS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| Market CapShares × price | $13M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $9M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.96x | -92.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 156.43x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5.77x | 11.74x |
| Price / BookPrice ÷ Book value/share | 3.03x | 3.02x |
| Price / FCFMarket cap ÷ FCF | — | 106.19x |
BLFS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
BLFS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BLFS delivers a -2.9% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-5 for FEMY. BLFS carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to FEMY's 0.80x. On the Piotroski fundamental quality scale (0–9), BLFS scores 6/9 vs FEMY's 2/9, reflecting solid financial health.
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| ROE (TTM)Return on equity | -5.3% | -2.9% |
| ROA (TTM)Return on assets | -116.3% | -2.6% |
| ROICReturn on invested capital | -3.5% | -2.8% |
| ROCEReturn on capital employed | -167.9% | -3.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | 0.80x | 0.05x |
| Net DebtTotal debt minus cash | -$5M | -$15M |
| Cash & Equiv.Liquid assets | $9M | $33M |
| Total DebtShort + long-term debt | $5M | $18M |
| Interest CoverageEBIT ÷ Interest expense | -8.85x | -18.62x |
BLFS leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BLFS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BLFS five years ago would be worth $7,300 today (with dividends reinvested), compared to $374 for FEMY. Over the past 12 months, BLFS leads with a +8.3% total return vs FEMY's -60.6%. The 3-year compound annual growth rate (CAGR) favors BLFS at 6.5% vs FEMY's -15.7% — a key indicator of consistent wealth creation.
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| YTD ReturnYear-to-date | -29.5% | -3.2% |
| 1-Year ReturnPast 12 months | -60.6% | +8.3% |
| 3-Year ReturnCumulative with dividends | -40.1% | +20.7% |
| 5-Year ReturnCumulative with dividends | -96.3% | -27.0% |
| 10-Year ReturnCumulative with dividends | -96.3% | +1221.1% |
| CAGR (3Y)Annualised 3-year return | -15.7% | +6.5% |
BLFS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FEMY and BLFS each lead in 1 of 2 comparable metrics.
Risk & Volatility
FEMY is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than BLFS's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BLFS currently trades 78.1% from its 52-week high vs FEMY's 38.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.67x |
| 52-Week HighHighest price in past year | $1.16 | $29.62 |
| 52-Week LowLowest price in past year | $0.31 | $17.86 |
| % of 52W HighCurrent price vs 52-week peak | +38.7% | +78.1% |
| RSI (14)Momentum oscillator 0–100 | 57.3 | 56.7 |
| Avg Volume (50D)Average daily shares traded | 513K | 422K |
Evenly matched — FEMY and BLFS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | FEMYFemasys Inc. | BLFSBioLife Solutions… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.00 |
| # AnalystsCovering analysts | — | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BLFS leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallBioLife Solutions, Inc. (BLFS)Leads 4 of 6 categories
Loading custom metrics...
FEMY vs BLFS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FEMY or BLFS a better buy right now?
For growth investors, Femasys Inc.
(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 17. 0% for BioLife Solutions, Inc. (BLFS). Analysts rate BioLife Solutions, Inc. (BLFS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FEMY or BLFS?
Over the past 5 years, BioLife Solutions, Inc.
(BLFS) delivered a total return of -27. 0%, compared to -96. 3% for Femasys Inc. (FEMY). Over 10 years, the gap is even starker: BLFS returned +1221% versus FEMY's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FEMY or BLFS?
By beta (market sensitivity over 5 years), Femasys Inc.
(FEMY) is the lower-risk stock at 1. 10β versus BioLife Solutions, Inc. 's 1. 67β — meaning BLFS is approximately 51% more volatile than FEMY relative to the S&P 500. On balance sheet safety, BioLife Solutions, Inc. (BLFS) carries a lower debt/equity ratio of 5% versus 80% for Femasys Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — FEMY or BLFS?
By revenue growth (latest reported year), Femasys Inc.
(FEMY) is pulling ahead at 40. 8% versus 17. 0% for BioLife Solutions, Inc. (BLFS). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to 43. 2% for BioLife Solutions, Inc.. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FEMY or BLFS?
BioLife Solutions, Inc.
(BLFS) is the more profitable company, earning -12. 6% net margin versus -812. 3% for Femasys Inc. — meaning it keeps -12. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BLFS leads at -12. 6% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — BLFS leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FEMY or BLFS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FEMY or BLFS better for a retirement portfolio?
For long-horizon retirement investors, BioLife Solutions, Inc.
(BLFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1221% 10Y return). Both have compounded well over 10 years (BLFS: +1221%, FEMY: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FEMY and BLFS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(FEMY: 39.9% · BLFS: 14.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.